Revvity stock rating reiterated at Overweight by KeyBanc despite lowered estimates

Investing.com - KeyBanc maintained its Overweight rating and $125.00 price target on Revvity Inc (NYSE:RVTY) in a research note issued Tuesday. According to InvestingPro data, the stock is currently trading near its 52-week low of $81.36, while analyst targets range from $100 to $162.

The investment firm reduced its estimates for Revvity to reflect management’s recent commentary indicating fiscal year 2025 operating margins of 27.1-27.3% and fiscal year 2026 organic growth of 2-3%.

Despite the lowered outlook, KeyBanc noted that Revvity’s current enterprise value to EBITDA multiple of 12.9x based on fiscal year 2026 estimates represents a significant discount of approximately 20% compared to peers and about 30% below its five-year average.

The research firm highlighted that Revvity’s current multiple is roughly the same as it was approximately six years ago, when operating margins were below 20%, compared to approximately 27% today.

KeyBanc described Revvity as an attractive option for value investors, noting the company’s long-term potential for high-single-digit growth while providing a deeper analysis of each of Revvity’s four business segments.

In other recent news, Revvity Inc. reported its second-quarter 2025 earnings, exceeding analyst expectations with an adjusted earnings per share of $1.18 compared to the forecasted $1.14. The company’s revenue reached $720 million, surpassing the anticipated $710.39 million. Despite these positive earnings results, several analyst firms have adjusted their price targets for Revvity. Stifel lowered its price target to $110, maintaining a Hold rating, due to pressures in China ImmunoDx. Raymond James also reduced its price target to $115, citing reimbursement headwinds in China, but maintained an Outperform rating. Bernstein SocGen Group adjusted its target to $115, noting that Revvity’s organic growth of 3% matched consensus estimates. Jefferies lowered the price target further to $100, pointing to adjustments related to China’s drug-related group policies. These recent developments highlight the impact of international factors on Revvity’s financial outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.